parkinson's disease retatrutide clinical trial Current Therapies in Trials of Disease: A 2021 Update GLP-1 Agonists: A New Frontier

[DOI] [PubMed] [Google Scholar] 23.Gebre-Medhin S, Mulder H, Pekny M, Westermark G, Trnell J, Westermark P, et al

N Engl J Med 2019;380:2295306

Retatrutide works through simultaneous activation of three metabolic receptors: GLP-1 (which reduces appetite and improves insulin secretion), GIP (which enhances insulin sensitivity and influences fat storage), and glucagon (which increases energy expenditure and promotes hepatic fat oxidation)

If you notice a site consistently causes more irritation than others, mention it at your next check-in, since some patients have body composition factors that make certain sites less ideal for them